$SATT
Sativus Tech Corp Stock $satt

$satt Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000168316824008058 Filed on November 14, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q4
Revenue			$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin			$150.0K
YoY Change			-11.76%
% of Gross Profit
Research & Development			-$48.00K
YoY Change			-126.82%
% of Gross Profit
Depreciation & Amortization			$21.00K
YoY Change			950.0%
% of Gross Profit
Operating Expenses			$102.0K
YoY Change			-70.77%
Operating Profit		-$155.0K
YoY Change		-42.16%
Interest Expense			-$152.0K
YoY Change			-58.13%
% of Operating Profit
Other Income/Expense, Net		$2.174M
YoY Change		73.64%
Pretax Income			-$254.0K
YoY Change			-64.33%
Income Tax
% Of Pretax Income
Net Earnings		$2.070M	-$224.0K
YoY Change		91.31%	-64.5%
Net Earnings / Revenue
Basic Earnings Per Share		$0.49
Diluted Earnings Per Share		$0.49	-$0.05
COMMON SHARES
Basic Shares Outstanding	4.216M shares	4.216M shares	4.216M shares
Diluted Shares Outstanding		4.216M shares

Balance Sheet

Concept	2024 Q3	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments		$813.0K
YoY Change		0.37%
Cash & Equivalents	$128.0K	$176.0K
Short-Term Investments		$637.0K
Other Short-Term Assets	$11.00K	$313.0K
YoY Change	-67.65%	268.24%
Inventory
Prepaid Expenses
Receivables
Other Receivables	$173.0K	$313.0K
Total Short-Term Assets	$323.0K	$1.137M
YoY Change	-72.88%	26.19%
LONG-TERM ASSETS
Property, Plant & Equipment	$465.0K	$256.0K
YoY Change	93.75%	16.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$468.0K	$271.0K
YoY Change	80.69%	8.84%
TOTAL ASSETS
Total Short-Term Assets	$323.0K	$1.137M
Total Long-Term Assets	$468.0K	$271.0K
Total Assets	$791.0K	$1.408M
YoY Change	-45.45%	22.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$38.00K	$46.00K
YoY Change	280.0%	-16.36%
Accrued Expenses		$13.00K
YoY Change		-59.38%
Deferred Revenue
YoY Change
Short-Term Debt		$2.074M
YoY Change		-3.31%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$3.130M
YoY Change		-15.84%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities		$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities		$3.130M
Total Long-Term Liabilities		$0.00
Total Liabilities	$3.275M	$3.130M
YoY Change	11.58%	-15.84%
SHAREHOLDERS EQUITY
Retained Earnings	-$23.48M	-$22.93M
YoY Change	3.43%	1.43%
Common Stock	$20.66M	$20.64M
YoY Change	0.06%	516000.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.827M	-$2.284M
YoY Change
Total Liabilities & Shareholders Equity	$791.0K	$1.408M
YoY Change	-45.45%	22.43%

Cashflow Statement

Concept	2024 Q3	2023 Q4
OPERATING ACTIVITIES
Net Income	$2.070M	-$224.0K
YoY Change	91.31%	-64.5%
Depreciation, Depletion And Amortization		$21.00K
YoY Change		950.0%
Cash From Operating Activities		-$302.0K
YoY Change		19.37%
INVESTING ACTIVITIES
Capital Expenditures		$31.00K
YoY Change		342.86%
Acquisitions
YoY Change
Other Investing Activities		$84.00K
YoY Change		1580.0%
Cash From Investing Activities		$53.00K
YoY Change		-2750.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		0.000
YoY Change		-100.0%
NET CHANGE
Cash From Operating Activities		-302.0K
Cash From Investing Activities		53.00K
Cash From Financing Activities		0.000
Net Change In Cash		-249.0K
YoY Change		-140.23%
FREE CASH FLOW
Cash From Operating Activities		-$302.0K
Capital Expenditures		$31.00K
Free Cash Flow		-$333.0K
YoY Change		28.08%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.88
	dei	Entity Central Index Key EntityCentralIndexKey	0001661600
CY2024Q3	us-gaap	Other Assets Current OtherAssetsCurrent	11000	usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	465000	usd
CY2024Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	468000	usd
CY2024Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	140000	usd
CY2024Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	2196000	usd
CY2024Q3	satt	Fair Value Of Convertible Component In Convertible Loans FairValueOfConvertibleComponentInConvertibleLoans	901000	usd
CY2024Q3	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	0	usd
CY2024Q3	us-gaap	Liabilities Liabilities	3275000	usd
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2024Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	20651000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23482000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-2827000	usd
CY2024Q3	us-gaap	Minority Interest MinorityInterest	343000	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2484000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	791000	usd
CY2024Q3	satt	Research And Development ResearchAndDevelopment	93000	usd
CY2023Q3	satt	Research And Development ResearchAndDevelopment	161000	usd
	satt	Research And Development ResearchAndDevelopment	417000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	62000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	107000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	194000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-155000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-268000	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2174000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-171000	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	2019000	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	984000	usd
	us-gaap	Profit Loss ProfitLoss	-782000	usd
CY2024Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-51000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	2070000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	1082000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-554000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.49
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4215571	shares
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense		usd
CY2024Q2	satt	Share Based Compensation To Noncontrolling Parties ShareBasedCompensationToNoncontrollingParties		usd
CY2024Q3	satt	Share Based Compensation To Noncontrolling Parties ShareBasedCompensationToNoncontrollingParties		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	333-208814
	dei	Entity Registrant Name EntityRegistrantName	SATIVUS TECH CORP.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-2847446
	dei	Entity Address Address Line1 EntityAddressAddressLine1	#3 Bethesda Metro Center
	dei	Entity Address Address Line2 EntityAddressAddressLine2	#700
	dei	Entity Address City Or Town EntityAddressCityOrTown	Bethesda
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20814
	dei	City Area Code CityAreaCode	800
	dei	Local Phone Number LocalPhoneNumber	608-6432
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	4215571	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	128000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	176000	usd
CY2024Q3	us-gaap	Deposits Assets Current DepositsAssetsCurrent	11000	usd
CY2023Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	637000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	11000	usd
CY2024Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	173000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	313000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	323000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1137000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	15000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	256000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	271000	usd
CY2024Q3	us-gaap	Assets Assets	791000	usd
CY2023Q4	us-gaap	Assets Assets	1408000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	38000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	46000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	112000	usd
CY2023Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	2074000	usd
CY2023Q4	satt	Fair Value Of Convertible Component In Convertible Loans FairValueOfConvertibleComponentInConvertibleLoans	885000	usd
CY2023Q4	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	13000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	3130000	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4215571	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4215571	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4215571	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4215571	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	20640000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-22928000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-2284000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	562000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1722000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1408000	usd
	satt	Research And Development ResearchAndDevelopment	301000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	412000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-611000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-713000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1252000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	380000	usd
	us-gaap	Profit Loss ProfitLoss	-333000	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-98000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-228000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-233000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-100000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.49
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.26
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.22
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4215571	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4215571	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4215571	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4215571	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4215571	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4820442	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4215571	shares
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1722000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	9000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-12000	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1725000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	6000	usd
CY2024Q2	us-gaap	Profit Loss ProfitLoss	-2789000	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4508000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5000	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	2019000	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2484000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2569000	usd
CY2023Q1	satt	Share Based Compensation To Noncontrolling Parties ShareBasedCompensationToNoncontrollingParties	39000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	35000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	1274000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-316000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1537000	usd
CY2023Q2	satt	Share Based Compensation To Noncontrolling Parties ShareBasedCompensationToNoncontrollingParties	26000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	35000	usd
CY2023Q2	us-gaap	Stock Granted During Period Value Sharebased Compensation Forfeited StockGrantedDuringPeriodValueSharebasedCompensationForfeited	14000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-1000000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2490000	usd
CY2023Q3	satt	Share Based Compensation To Noncontrolling Parties ShareBasedCompensationToNoncontrollingParties	19000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2000	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	984000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1485000	usd
	us-gaap	Profit Loss ProfitLoss	-782000	usd
	us-gaap	Profit Loss ProfitLoss	-333000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	84000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	39000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	142000	usd
	satt	Financial Expenses Related To Convertible Loans And Warrants FinancialExpensesRelatedToConvertibleLoansAndWarrants	122000	usd
	satt	Financial Expenses Related To Convertible Loans And Warrants FinancialExpensesRelatedToConvertibleLoansAndWarrants	122000	usd
	satt	Change In Fair Value Of Convertible Component In Convertible Loans ChangeInFairValueOfConvertibleComponentInConvertibleLoans	15000	usd
	satt	Change In Fair Value Of Convertible Component In Convertible Loans ChangeInFairValueOfConvertibleComponentInConvertibleLoans	-565000	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-140000	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-51000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-7000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-45000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	28000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-41000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-380000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-630000	usd
	us-gaap	Payments For Proceeds From Other Deposits PaymentsForProceedsFromOtherDeposits	-626000	usd
	us-gaap	Payments For Proceeds From Other Deposits PaymentsForProceedsFromOtherDeposits	726000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	281000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	48000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	345000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-774000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	13000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	14000	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	-0	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	126000	usd
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	-0	usd
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	114000	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	1273000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-13000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1019000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-48000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-385000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	176000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	810000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	128000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	425000	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	satt	Conversion Of Convertible Loans ConversionOfConvertibleLoans	0	usd
	satt	Conversion Of Convertible Loans ConversionOfConvertibleLoans	0	usd
	satt	Purchase Of Fixed Assets By Issuance Of Share Capital PurchaseOfFixedAssetsByIssuanceOfShareCapital	0	usd
	satt	Purchase Of Fixed Assets By Issuance Of Share Capital PurchaseOfFixedAssetsByIssuanceOfShareCapital	0	usd
	us-gaap	Basis Of Accounting BasisOfAccounting	<p id="xdx_801_eus-gaap--BasisOfAccounting_zvaMFk0Rioyj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1:-</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82D_zkSIcaZTIX3g">GENERAL</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SATIVUS TECH CORP. (formerly SEEDO CORP.) (the “Company”, “Our” or “We”) was formed on January 16, 2015, under the laws of the State of Delaware. Prior to July 2020, we were involved in producing a plant growing device managed and controlled by an artificial intelligent algorithm, allowing consumers to grow their own herbs and vegetables effortlessly from seed to plant, while providing optimal conditions to assure premium quality produce year-round. However, due to financial and operational difficulties and during 2020, we ceased these operations and on July 19, 2020, the Company formed a new wholly-owned subsidiary in Israel, Hachevra Legiduley Pkaot Beisrael Ltd. (the “New Subsidiary”), to develop a fully automated and remotely managed system for growing saffron and other vegetables. On November 5, 2020, the New Subsidiary changed its name to Saffron-Tech Ltd. (or “Saffron Tech”). As of the date of this report, and following various financings in Saffron Tech, the Company owns 59% of Saffron Tech.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company, through Saffron Tech, is focusing on its in-house research and development of agriculture technology products, among others, in the fields of exotic plants . Saffron Tech plans to roll out its proof of concept in the coming months. This technology will provide turnkey automated growing containers for high-quality, high-yield saffron all year round. The Company is in advanced stages of developing and testing a fully automated and remotely managed system for growing high-quality, high-yield saffron anywhere and anytime.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">It is also environmentally friendly, using economic levels of water, space, fertilizer, and energy. Accounting to the Company’s calculations, we believe that the controlled indoor growing area will produce ten times more yield compared to the same land area using traditional methods. The sealed environment eliminates the need for herbicides, producing a clean and safe product that is easy to control from anywhere. The Company’s solution is easily scalable and pre-designed to quickly grow operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Saffron is used in many industries, such as the food industry, particularly by famous chefs and Michelin starred restaurants, the natural cosmetics industry and the food supplements industry and as a dye in the food industry. Medicinal claims as an anti-depressant, antioxidant, and antiseptic are constantly increasing.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has an accumulated deficit in the total amount of $<span id="xdx_909_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20240930_zwwUlXdCFNN8" title="Accumulated deficit">23,482</span> as of September 30, 2024, the Company has negative operating cash flow in the total amount of $<span id="xdx_907_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20240101__20240930_zppKTKzgzm7c" title="Negative operating cash flow amount">380</span> for the nine months ended September 30, 2023, further losses are anticipated in the development of its business. Those factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company intends to finance operating costs over the next twelve months with existing cash on hand, reducing operating spend, and future issuances of equity and debt securities, or through a combination of the foregoing. However, the Company will need to seek additional sources of financing if the Company requires more funds than anticipated during the next 12 months or in later periods.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The consolidated financial statements for the nine months ended September 30, 2024, do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern.</p>
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23482000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-380000	usd
	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	0	usd
	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	186000	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	8000	usd
	satt	Related Party Expense RelatedPartyExpense	194000	usd
CY2024Q3	satt	Due To Related Party DueToRelatedParty	-152000	usd
	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	0	usd
	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	277000	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	29000	usd
	satt	Related Party Expense RelatedPartyExpense	306000	usd
CY2023Q3	satt	Due To Related Party DueToRelatedParty	-127000	usd
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4215571	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4215571	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4215571	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4215571	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	198750	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.40
CY2023	satt	Warrants Granted WarrantsGranted	0	shares
CY2023	satt	Average Exercise Price Granted AverageExercisePriceGranted	0
CY2023	satt	Warrants Exercised WarrantsExercised	0	shares
CY2023	satt	Average Exercise Price Exercised AverageExercisePriceExercised	0
CY2023	satt	Warrants Outstanding Forfeitedcancelled WarrantsOutstandingForfeitedcancelled	-13750	shares
CY2023	satt	Average Exercise Price Forfeitedcancelled AverageExercisePriceForfeitedcancelled	2.00
CY2023	satt	Warrants Outstanding Forfeitedcancelled1 WarrantsOutstandingForfeitedcancelled1	-66000	shares
CY2023	satt	Average Exercise Price Forfeitedcancelled1 AverageExercisePriceForfeitedcancelled1	1.50
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	119000	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.88
	satt	Warrants Granted WarrantsGranted	0	shares
	satt	Average Exercise Price Granted AverageExercisePriceGranted	0
	satt	Warrants Exercised WarrantsExercised	0	shares
	satt	Average Exercise Price Exercised AverageExercisePriceExercised	0
	satt	Warrants Outstanding Forfeitedcancelled WarrantsOutstandingForfeitedcancelled	0	shares
	satt	Average Exercise Price Forfeitedcancelled AverageExercisePriceForfeitedcancelled	0
CY2024Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	119000	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	119000	shares
CY2023Q4	satt	Class Of Warrant Or Right Outstanding And Exercisable ClassOfWarrantOrRightOutstandingAndExercisable	119000	shares
CY2024Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	119000	shares
CY2024Q3	satt	Class Of Warrant Or Right Outstanding And Exercisable ClassOfWarrantOrRightOutstandingAndExercisable	119000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	240000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.7
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	-80000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.1
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	160000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.05
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	0	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	160000	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.05
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	160000	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.05
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	160000	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	160000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	536000	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares
CY2023	satt	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised	0	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	5000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	531000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares
	satt	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	5000	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	531000	shares
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2174000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1252000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-171000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	380000	usd
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001683168-24-008058-index-headers.html	Edgar Link	pending
0001683168-24-008058-index.html	Edgar Link	pending
0001683168-24-008058.txt	Edgar Link	pending
0001683168-24-008058-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
sativus_ex3101.htm	Edgar Link	pending
sativus_ex3102.htm	Edgar Link	pending
sativus_ex3201.htm	Edgar Link	pending
sativus_ex3202.htm	Edgar Link	pending
sativus_i10q-093024.htm	Edgar Link	pending
satt-20240930.xsd	Edgar Link	pending
satt-20240930_cal.xml	Edgar Link	unprocessable
satt-20240930_def.xml	Edgar Link	unprocessable
satt-20240930_lab.xml	Edgar Link	unprocessable
sativus_i10q-093024_htm.xml	Edgar Link	completed
Show.js	Edgar Link	pending
satt-20240930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SATT
Sativus Tech Corp Stock $satt

2024 Q4 Form 10-Q Financial Statement

#000168316824008058 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SATT Sativus Tech Corp Stock $satt

2024 Q4 Form 10-Q Financial Statement

#000168316824008058 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SATT
Sativus Tech Corp Stock $satt